Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2020-06-09

FDA Approved: LASTACAFT — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for LASTACAFT (alcaftadine) from Allergan, resulting in changes to the labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lastacaft (Alcaftadine)

Snippet

SUPPL AP for LASTACAFT (ALCAFTADINE)